133 related articles for article (PubMed ID: 21572303)
1. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Gonzalez E; Ballana E; Clotet B; Esté JA
AIDS; 2011 Aug; 25(13):1557-83. PubMed ID: 21572303
[TBL] [Abstract][Full Text] [Related]
2. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.
González-Ortega E; Ballana E; Badia R; Clotet B; Esté JA
Antiviral Res; 2011 Dec; 92(3):479-83. PubMed ID: 22027647
[TBL] [Abstract][Full Text] [Related]
3. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
5. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.
Forssmann WG; The YH; Stoll M; Adermann K; Albrecht U; Tillmann HC; Barlos K; Busmann A; Canales-Mayordomo A; Giménez-Gallego G; Hirsch J; Jiménez-Barbero J; Meyer-Olson D; Münch J; Pérez-Castells J; Ständker L; Kirchhoff F; Schmidt RE
Sci Transl Med; 2010 Dec; 2(63):63re3. PubMed ID: 21178138
[TBL] [Abstract][Full Text] [Related]
6. An optimized MM/PBSA virtual screening approach applied to an HIV-1 gp41 fusion peptide inhibitor.
Venken T; Krnavek D; Münch J; Kirchhoff F; Henklein P; De Maeyer M; Voet A
Proteins; 2011 Nov; 79(11):3221-35. PubMed ID: 21989940
[TBL] [Abstract][Full Text] [Related]
7. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
8. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
[TBL] [Abstract][Full Text] [Related]
9. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
10. Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction.
Sen J; Yan T; Wang J; Rong L; Tao L; Caffrey M
Biochemistry; 2010 Jun; 49(24):5057-65. PubMed ID: 20481578
[TBL] [Abstract][Full Text] [Related]
11. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
12. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
13. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
14. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
Lohrengel S; Hermann F; Hagmann I; Oberwinkler H; Scrivano L; Hoffmann C; von Laer D; Dittmar MT
J Virol; 2005 Aug; 79(16):10237-46. PubMed ID: 16051817
[TBL] [Abstract][Full Text] [Related]
15. Targeting the sticky fingers of HIV-1.
Blumenthal R; Dimitrov DS
Cell; 2007 Apr; 129(2):243-5. PubMed ID: 17448985
[TBL] [Abstract][Full Text] [Related]
16. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
[TBL] [Abstract][Full Text] [Related]
18. HIV entry inhibitors: mechanisms of action and resistance pathways.
Briz V; Poveda E; Soriano V
J Antimicrob Chemother; 2006 Apr; 57(4):619-27. PubMed ID: 16464888
[TBL] [Abstract][Full Text] [Related]
19. Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes.
Zhou X; Liu Z; Zhang J; Adelsberger JW; Yang J; Burton GF
BMC Microbiol; 2016 Jul; 16(1):172. PubMed ID: 27473095
[TBL] [Abstract][Full Text] [Related]
20. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
